GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF GlobeNewswire January 28, 2026 Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” […]

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI GlobeNewswire January 28, 2026 NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28,

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 GlobeNewswire January 28, 2026 – Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA submission – LOS

Skulpty, a 3D AI company focused on solving topology for next-generation models, today announced it is opening a new investment round to support strategic partnerships and go-to-market expansion as its MVP enters final preparation for launch in Q1. Rather than a traditional capital-raise announcement, the company is emphasizing relationships with partners who can help bring

On a mission to end robot blindness, Apera AI is making 4D Vision-guided robotic deployments faster, more predictable, and highly repeatable. The newest Apera Vue release introduces Programmable Autopilot for optimal multi-step collision-free path planning, Range Finding for unstructured de-racking, and 4X faster AI training with Apera Forge. Apera AI, the leader in 4D Vision

PowerComps by TagniFi has released its Q4-2025 Market Conditions and Valuation report, highlighting continued resilience in middle-market M&A valuations amid constrained deal activity. Despite a subdued transaction environment, valuations held firm, driven by strategic fit and operational fundamentals rather than volume or leverage. “2025 wasn’t about how many deals got done — it was about

Compass Surgical Partners (Compass), a leading, independent, full-service ambulatory surgery center (ASC) development and management partner, today announced that it has partnered with local physicians to develop and launch the Cardiovascular Surgical Institute of Northwest Florida. Located in Panama City, the 8,000-square-foot outpatient facility offers interventional cardiology, electrophysiology, and vascular surgery procedures. First cases began

Company strengthens its AI-native platform foundation, scales multi-solution enterprise deployments, and advances autonomous supply chain capabilities with RADAR Decklar, the Real-Time Decision AI platform for global supply chains, today announced strong commercial momentum exiting 2025, including 48% year-over-year revenue growth, adjusted EBITDA positive for 3 quarters, cash-neutral from operations, and having an average customer contract

Equality Asset Management (“EAM”), a Boston-based private equity firm focused on investing in transformative growth software and technology companies, today announced the closing of its second fund, EAM Private Equity Partners II, L.P. (“EAM Fund II” or “the Fund”) with $575 million in total capital commitments. The Fund was oversubscribed with demand significantly exceeding its

Detroit, Michigan–(Newsfile Corp. – January 28, 2026) – Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the “Company”), a global leader in AI-driven security and productivity solutions, along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today reported that its RIO™ autonomous security towers have been surpassing their original extreme weather performance estimates as demonstrated by